Novartis Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

99,88 EUR -0,62 EUR -0,62 %

30.04.2025

L&S

93,35 CHF -0,78 CHF -0,82 %

30.04.2025

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.189,96 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

06.06.22Dow JonesPress Release: Novartis Tafinlar(R) (dabrafenib) -2-

06.06.22Dow JonesPress Release: Novartis Tafinlar(R) (dabrafenib) + Mekinist(R) (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grad...

31.05.22GlobeNewswireSandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030

31.05.22Dow JonesPress Release: Novartis: Sandoz announces new global 'Act4Biosimilars' initiative, to improve patient access and increase adoption by at least 30% in 30+ cou...

28.05.22GlobeNewswireFDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

27.05.22GlobeNewswireSandoz appoints new Board representative to global AMR Industry Alliance

27.05.22Dow JonesPress Release: Novartis: Sandoz appoints new Board representative to global AMR Industry Alliance

20.05.22GlobeNewswireNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

20.05.22Dow JonesPress Release: Novartis Cosentyx(R) (secukinumab) -2-

20.05.22Dow JonesPress Release: Novartis Cosentyx(R) (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

12.05.22GlobeNewswireNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

04.05.22GlobeNewswireNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients

04.05.22Dow JonesPress Release: New Novartis data demonstrate only -2-

04.05.22Dow JonesPress Release: New Novartis data demonstrate only Kisqali(R) offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer p...

27.04.22Dow JonesPress Release: Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phas...

26.04.22Dow JonesPress Release: Novartis delivers solid sales and -4-

26.04.22Dow JonesPress Release: Novartis delivers solid sales and -2-

26.04.22Dow JonesPress Release: Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

22.04.22Dow JonesPress Release: Novartis receives positive CHMP -2-

22.04.22Dow JonesPress Release: Novartis receives positive CHMP opinion for Tabrecta(R) for patients with METex14 advanced non-small cell lung cancer

14.04.22Dow JonesPress Release: Novartis: Sandoz launches generic -2-

14.04.22Dow JonesPress Release: Novartis: Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ...

06.04.22Dow JonesPress Release: Novartis: Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

05.04.22Dow JonesPress Release: Novartis expands Zolgensma -2-

05.04.22Dow JonesPress Release: Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility

04.04.22Dow JonesPress Release: Novartis announces new -2-

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.